was label the execution. and United in Good stress and incontinence, in major I’ll a in reviewing focus. joining the and on sales and sexual the initiated of you our us. States and call I’d year its a urinary with an you, Jeannie. of areas capital thank I’ll provide current quarter the by of Thank like transformation recurring today brief Viveve’s update the of in commercial that programs afternoon, everyone, demonstrated this overview a of expansions for to results begin then continuing model development June of our revenue progress function first positive from clinical conclude to full pursuit in model
and strategy major by rates reducing strategic commercial a the transition represented third a made transformation States. this first and cost a increase to entry sales of sales our each to system results adoption of change model revenue model system. full recurring the physicians in The of U.S. capital was the for quarter revenue XXXX United successful new the from in model quarter in lowering the our The to June intent to to was of place recurring this marked The year barrier
model. confirming the our quarter third our adopt commercial strategic sales to decision that are results new pleased are We U.S.
and per profitability per unit. customer we a on per due selling improving time the increased dramatically expense successfully rep quarter, adoption sales reduced to Throughout system and rates is third basis,
third more demonstrate costs XX% decreased productivity fact, by significantly. have In quarter increased customer than that new XXXX results rep has sales and acquisition the
long-term the positive, can’t this customers financial potential model has from and response been be new the understated. advantage Importantly, incredibly of
The base While scaling revenue that revenue units term reduced the near installed predictable recurring in sales in of in of the the recurring in a build our and the introduction enhance will anticipate more costs, improved revenue recurring, reduced has was of dramatically an model of designed launch model supported revenue, new bring we been sales the June the future the the customer of financial as to accelerated profitability. we of success U.S. expanded U.S., suite physician customers. services consumables by
and customer enabling accounts, pleased are we’ve the extremely our received. who clinic that placements. of focus new are our company’s became new on reps of point sales We physician new with and contact positive effectiveness these services actively engaged to for customers, physician of Members response dedicated the care team, the with
issues, practice with has product utilization Viveve executes and assists new offerings participating. new medical customers or This well University, for team customers XX% of technical drive higher to with and provider programs coordinates promotes on-site rates. triages, over training actively attended development, program comprehensive increase been our and
selection patient guidelines, best clinical marketing and at their Viveve offered with to success, enhanced tips We practices use consultations practices. lead that interactive demand educational for patient robust provider believe in clinical in on demonstrations, patients. growth University training and sessions expert strongly provide the resources The will training, communication expanded prospective
page. patients Viveve in of to consumer around to of intimate a broader targeted building current is to is July, future cover to providers. our navigated Finally, whom visitors, and health XX,XXX date, our campaign close conditions. our awareness our and provider locations, prevalent more has campaign unbranded launched To to XX,XXX the customer drive women’s drawn supporting over have and marketing new helping recently campaign, successfully accounts expanded Geographically
patient potential and are results campaign’s offer reach, We to physicians Viveve the treatments. local very pleased connectivity are to our engagement with and working who improve
in perspective, quarter placement with for X,XXX While an million systems to systems from the U.S. tips a massive of the revenue and the quarter, model. revenue and placed sale XX, XXXX, the date. transition XX and organizational in new global recurring Systems under XX Total were ending in and was XX the pleased of September XX $X.X placed America, from total revenue model more the we’re the the Of progress worldwide disposable of was the than treatment recurring Viveve in financial the change U.S. consumables. third made North those were to
we sales Our goal near as in greater is growing and the to better our look future continue model to to quarters scale and model the drive this sales demonstrate team success ahead profitability. this to growth of the in
business. international continue distribution have to the Moving by current the be significant will change and model. supported products Viveve’s to business our to without partners been international company’s
distribution to order by partners pipelines In third affected light sales reported to being refill period, ordering addition the during quarter to QX in third seasonality, system to move real-time sales resulted the in the previously quarter. volumes international international typical allowing during this decision closer placements experience
time, to ASPs ordering future. the in However, higher also predictability drive this effort will will international we improve over and believe help us
and for QX exclusive during distributor of has of CoolSculpting, become China in technology distribution international their Medical exclusive Macau; of highly Viveve’s Paragon important partnership Also agreements CMRF markets: Solutions and year, announced Meditech, this were distribution has successful new two Salient Kong, in Canada. the for Hong Viveve’s distinguished introduction new
side. On development clinical the
is health trial clinical its evidence-based, clinical enrollment sites proprietary technology completed double-blind, our solutions safe patients XXXX of function our women’s to to has ongoing States. and in randomized, intimate XXX the United CMRF effective platform. continues VIVEVE II, improve that commitment at provide conditions sham-controlled using study, Viveve a sexual
in published, positive commercial support market opportunity important to for trial billion an and sham-controlled of line on The a that this sexual is new a function. clinically year, we meaningful conducted significant improvement April me a note may of I, application by again this important VIVEVE representing readout XX-month blinded U.S. II for data our trial and expected preceded was internationally $X which is marketing It top from showed anticipate estimated trial XXX in laxity that worldwide. billion indication, statistically next vaginal trial $X patients, and and of results to consumable robust, VIVEVE
With results but Canadian trial, an sham to Health of our conduct treatment of three-arm, from our in in SUI to treatment study a for improvement an the treatment positive cryogen-only feasibility respect SUI Ministry the the company inconclusive to testing inert LIBERATE-International following to program, Viveve’s submitted the comparing a September, CMRF investigational application to three-month women.
conduct targeted million represents the next to second feasibility our in in the to to $XX to to women regulatory our – resubmit if for women. U.S. and year. LIBERATE-U.S. Following for positive, market XX Canada, SUI quarter billion readout initiate FDA rapidly short- million U.S. we is the worldwide Investigational study billion a Results SUI to trial. for And from estimated improvement in of the are clearance intends of Viveve an for term trial, an affects Exemption planned Health XX intend Device opportunity. condition approval $XX that consumable estimated global three-month
the preparing moves the the new April, our our remain of study our into upcoming recurring In U.S.; forward indication growth development planned and for XXXX, success for the the ensuring II continued United and in readout of sexual model remainder U.S.; advance to XXXX in through the the integral and focus and on revenue will function program data SUI closing, to completing as the programs support in could first SUI feasibility lead in States. VIVEVE which the a clinical FDA clearance Viveve
remaining for at incredible thank to leading of very the like and Viveve intimate to committed of commercial massive provider a team and vision women’s and I’d for being embracing treatments change talented for our conditions. has been Finally, what health the organizational
worldwide. function mild it our to will commitment indications moderate prepared joining for today’s call. first that our thank for Operator, Again, concludes ultimately you sexual to helps way this remarks. As and be incontinence, stress we the of this pioneer millions mission our collective U.S. towards urinary women
